Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albenatide
- Development stage
- Phase 3
- Lead developer
- ConjuChem
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
**Albenatide** is a long-acting synthetic peptide analog of exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-weekly subcutaneous injection to treat type 2 diabetes mellitus (T2D). It employs PC-DAC™ technology to conjugate the active peptide to recombinant human albumin, extending its half-life and improving patient compliance compared to daily GLP-1 therapies. Developed initially by ConjuChem Biotechnologies and advanced in China by Hebei Changshan Biochemical Pharmaceutical (Kaijiejian Biopharmaceutical) in collaboration with Albumedix, albenatide has demonstrated efficacy in improving glycemic control in phase II trials and is currently in phase III trials, with NDA/BLA filing and IND approval for obesity.[1][2][4][5]
- Other names
- 艾本那肽Exendin-4-albumin conjugateExendin4-albumin conjugateExendin 4-albumin conjugateAlbenatide Injection
02
Targets
Beyond the preview
Go deeper on albenatide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albenatide.